DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 55 filers reported holding DANAHER CORPORATION in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.4%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $136,793 | -93.6% | 591 | -93.2% | 0.03% | -94.2% |
| Q3 2023 | $2,147,368 | +0.0% | 8,655 | -3.2% | 0.59% | +5.0% |
| Q2 2023 | $2,146,850 | -5.5% | 8,945 | -0.7% | 0.56% | -11.9% |
| Q1 2023 | $2,271,174 | -4.6% | 9,011 | +0.5% | 0.64% | -2.9% |
| Q4 2022 | $2,380,587 | +3.4% | 8,969 | +0.6% | 0.66% | +0.8% |
| Q3 2022 | $2,303,000 | +4.3% | 8,917 | +2.4% | 0.65% | +12.7% |
| Q2 2022 | $2,208,000 | -13.4% | 8,710 | +0.2% | 0.58% | +5.9% |
| Q1 2022 | $2,550,000 | -10.9% | 8,693 | -0.1% | 0.54% | -8.1% |
| Q4 2021 | $2,863,000 | +10.5% | 8,702 | +2.2% | 0.59% | +1.0% |
| Q3 2021 | $2,592,000 | +14.6% | 8,516 | +1.0% | 0.59% | +13.3% |
| Q2 2021 | $2,262,000 | +37.1% | 8,432 | +15.0% | 0.52% | +26.0% |
| Q1 2021 | $1,650,000 | -4.1% | 7,332 | -5.3% | 0.41% | +5.1% |
| Q4 2020 | $1,720,000 | +6.8% | 7,745 | +3.5% | 0.39% | -2.2% |
| Q3 2020 | $1,610,000 | +29.5% | 7,480 | +6.4% | 0.40% | +20.1% |
| Q2 2020 | $1,243,000 | +27.7% | 7,030 | 0.0% | 0.33% | +14.8% |
| Q1 2020 | $973,000 | -11.9% | 7,030 | -2.3% | 0.29% | +16.9% |
| Q4 2019 | $1,104,000 | +12.5% | 7,195 | +5.9% | 0.25% | +8.8% |
| Q3 2019 | $981,000 | +2.6% | 6,795 | +1.5% | 0.23% | +5.6% |
| Q2 2019 | $956,000 | +9.1% | 6,695 | 0.0% | 0.22% | +8.0% |
| Q1 2019 | $876,000 | +27.0% | 6,695 | 0.0% | 0.20% | +11.1% |
| Q4 2018 | $690,000 | -3.9% | 6,695 | +1.2% | 0.18% | +14.6% |
| Q3 2018 | $718,000 | +15.2% | 6,615 | +4.8% | 0.16% | +9.8% |
| Q2 2018 | $623,000 | -2.2% | 6,315 | -3.1% | 0.14% | -3.4% |
| Q1 2018 | $637,000 | +5.5% | 6,515 | 0.0% | 0.15% | +5.7% |
| Q4 2017 | $604,000 | +8.2% | 6,515 | 0.0% | 0.14% | +3.7% |
| Q3 2017 | $558,000 | +7.3% | 6,515 | 0.0% | 0.14% | +4.7% |
| Q2 2017 | $520,000 | +7.9% | 6,515 | +15.5% | 0.13% | +6.6% |
| Q1 2017 | $482,000 | +9.8% | 5,640 | -0.1% | 0.12% | +1.7% |
| Q4 2016 | $439,000 | +46.8% | 5,645 | +47.8% | 0.12% | +40.0% |
| Q3 2016 | $299,000 | -20.3% | 3,820 | +2.8% | 0.08% | -22.7% |
| Q2 2016 | $375,000 | +9.3% | 3,715 | +2.8% | 0.11% | +6.8% |
| Q1 2016 | $343,000 | +53.8% | 3,615 | +50.6% | 0.10% | +60.9% |
| Q4 2015 | $223,000 | – | 2,400 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |